If both treatments make sense on their own, can I use them together?
Do not assume so. Guidelines grade evidence for the exact pair, not for "two reasonable treatments." A short, named list of psoriasis combinations carries that kind of evidence. Most other pairings a reader might consider do not appear on it. Evidence Evidence
What is known
- Sources cited, not yet graded
Joint AAD-NPF guidelines name a small set of graded combinations. Acitretin with PUVA or with broadband UVB is one pair. A fixed calcipotriene/betamethasone product added to adalimumab or to low-dose cyclosporine is another. Topical tazarotene with narrowband UVB is the third.
What is uncertain
- Depends on you
A pairing missing from this list is not proven unsafe - it may simply be ungraded. Evidence for a named pairing does not transfer to a different drug, a different biologic, or a different dose. Whether an untested combination is reasonable for you is a question for your clinicians, not a general rule.
Questions for the clinicians coordinating the plan
Has this exact combination been graded in a guideline, or are we extrapolating?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does adding acitretin to phototherapy actually help?
For the exact pairings graded, yes. A guideline-cited trial found more patients cleared with PUVA plus acitretin than with PUVA alone, using a lower cumulative UVA dose. A separate finding describes acitretin combined with broadband UVB clearing patches faster than UVB alone, with a lower cumulative dose. Evidence
What is known
- Sources cited, not yet graded
The joint AAD-NPF phototherapy guideline gives a grade-B recommendation for acitretin with PUVA. It cites one 60-patient trial of severe psoriasis. 96 percent cleared with the combination, against 80 percent on PUVA alone, using 43 percent less cumulative UVA. It also records acitretin combined with broadband UVB. That pairing clears patches faster than UVB alone, with a lower cumulative dose.
What is uncertain
- Depends on you
The cited trial is 60 patients, not a larger pooled result. It studied PUVA, not narrowband UVB. Acitretin carries its own pregnancy contraindication and monitoring needs this source does not detail. A grade-B recommendation is not the guideline’s highest grade.
Questions for the clinicians coordinating the plan
Does the acitretin-PUVA trial resemble my situation?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What monitoring would adding acitretin to my phototherapy add?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does combining a fixed calcipotriene/betamethasone product with a biologic or with cyclosporine help?
The joint AAD-NPF topical guideline recommends both, each at Level I, Grade B. One adds it to standard-dose adalimumab for 16 weeks, to accelerate clearance. The other adds it to low-dose cyclosporine. Evidence
What is known
- Sources cited, not yet graded
The guideline names the exact pairings and regimens it grades. One is calcipotriene/betamethasone dipropionate added to standard-dose adalimumab for 16 weeks. The other is the same product added to low-dose cyclosporine (2 mg/kg/day) instead. Both target moderate to severe psoriasis.
What is uncertain
- Depends on you
Named for adalimumab specifically, not a different biologic. Named for the stated low-dose cyclosporine regimen, not a different dose. The guideline gives no efficacy percentage for the combination against either ingredient used alone.
Questions for the clinicians coordinating the plan
Would adding a topical to my current biologic or cyclosporine follow this exact regimen?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who coordinates my topical and systemic prescriptions?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does combining topical tazarotene with narrowband UVB help?
The same guideline grades this Level II, Grade B: the combination works, and it cuts the total narrowband UVB a course uses. Evidence
What is known
- Sources cited, not yet graded
The guideline names topical tazarotene combined with narrowband UVB as effective, at Level II, Grade B. It also names the combination as reducing total UVB use.
What is uncertain
- Depends on you
A Level II recommendation is a lower grade than the Level I ones named elsewhere in the same guideline. Tazarotene alone can raise light sensitivity. Timing an application around a phototherapy session is a clinician instruction, not a general rule. No specific reduction percentage is given.
Questions for the clinicians coordinating the plan
If we add tazarotene, how does that change my phototherapy schedule?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Who should coordinate my combination plan?
Before proceeding, know which pairing is being proposed and whether it is one of the graded combinations above. Know who owns the written instructions, too. Application order, dose, and any change to the plan belong with that person. Evidence Evidence
What is known
- Sources cited, not yet graded
Both guidelines are written for the clinicians who coordinate a psoriasis treatment plan. Each named combination above sits inside a supervised regimen, with its own duration and dose. None is a self-directed plan.
What is uncertain
- Depends on you
Coordination cannot guarantee a result or remove every uncertainty. If your prescribing and phototherapy or topical teams give conflicting instructions, ask the treating team to resolve it rather than choosing between them yourself.
Questions for the clinicians coordinating the plan
What is each treatment in this combination supposed to add?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who resolves it if my written instructions conflict?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the American Academy of Dermatology (Elmets CA, Korman NJ, Prater EF, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: A joint guideline from a specialty group and a patient group. Authors state their own industry ties in the article. It grades evidence with authority, not proof for one reader.
What this source supports
Supports a top grade (Level I, Grade A) for calcipotriene foam. The same top grade applies to calcipotriene plus betamethasone gel. Both are used for 4 to 12 weeks, for mild to moderate scalp psoriasis. Supports a Level I, Grade B recommendation for adding calcipotriene/betamethasone to standard-dose adalimumab for 16 weeks, to speed clearance in moderate to severe psoriasis. Gives that same grade for adding it to low-dose cyclosporine (2 mg/kg/day) instead. Supports a Level II, Grade B finding: tazarotene with narrowband UVB works, and cuts the total UVB a course uses. The full article text could not be fetched; automated retrieval was blocked. These figures were checked against other reporting of the same guideline instead, including a summary site's own quoted text.
What it does not support
Does not show the same benefit for a biologic other than adalimumab. Does not show it above the low-dose cyclosporine studied. Gives no efficacy percentage for the combination against either drug alone. Sets no duration, strength or dose for a reader to follow without a prescriber. Its authors disclose industry ties. It is US guidance.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the American Academy of Dermatology (Elmets CA, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: A joint guideline from a specialty society and a patient group. Authors report their own conflicts in the published article. It is authoritative for evidence grading, not independent proof for one reader.
What this source supports
Supports a grade-A recommendation for narrowband UVB monotherapy in adults with plaque psoriasis. Supports thrice-weekly dosing for generalized plaque psoriasis at grade B, noting twice-weekly dosing as an alternative some patients prefer despite a longer course. Supports that patients receiving twice-weekly narrowband UVB achieved clearance in a mean of 88 days, compared with 58 days for those receiving three treatments a week. Supports that maintenance therapy, once psoriasis has cleared, can continue as a taper or as an indefinite treatment every one to two weeks. Supports a grade-B recommendation for combining acitretin with PUVA. Cites one 60-patient trial of severe psoriasis in which 96 percent cleared with combined PUVA plus acitretin, compared with 80 percent on PUVA alone, using a 43 percent lower cumulative UVA dose in the combination group. Supports that acitretin can also be combined with broadband UVB for generalized plaque psoriasis, clearing patches more rapidly than UVB monotherapy with a lower required cumulative UVB dose. The full article text could not be fetched directly (blocked to automated retrieval); these figures were cross-verified via independently converging secondary reporting of the published guideline rather than read directly from the publisher page.
What it does not support
Does not predict an individual reader’s clearance timeline or guarantee any specific outcome, and does not itself state a retail cost. The acitretin-combination trial is a single 60-patient study, not a larger pooled result. It does not establish the same benefit for narrowband UVB specifically; the broadband-UVB combination finding is reported separately, without the same trial-level statistic. Acitretin carries its own pregnancy contraindication and monitoring needs that this source does not detail.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.